Flucytosine monotherapy for cryptococcosis

Duane R. Hospenthal, John E. Bennett

Research output: Contribution to journalArticle

Abstract

Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. Reported documentation of this widely accepted belief is surprisingly scarce. Therefore, we reviewed our experience with 5-FC monotherapy for 27 patients treated between 1968 and 1973. Patients were selected on the basis of criteria associated with good prognosis. In this group, 5-FC monotherapy resulted in cure in eight cases and improvement in two. Overall, response was seen in 10 (43%) of 23 evaluable patients. Therapy failed for 13 patients, including 5 who relapsed, 2 who had partial responses, and 6 without response. Resistance was noted to have developed in isolates from six (50%) of 12 patients for whom therapy failed. Although the 57% failure rate associated with 5-FC alone precludes its use as monotherapy, our study did show that this treatment was well tolerated and that failure was not invariably associated with development of resistance.

Original languageEnglish (US)
Pages (from-to)260-264
Number of pages5
JournalClinical Infectious Diseases
Volume27
Issue number2
StatePublished - 1998
Externally publishedYes

Fingerprint

Flucytosine
Cryptococcosis
Therapeutics
Drug Resistance
Documentation

ASJC Scopus subject areas

  • Immunology

Cite this

Hospenthal, D. R., & Bennett, J. E. (1998). Flucytosine monotherapy for cryptococcosis. Clinical Infectious Diseases, 27(2), 260-264.

Flucytosine monotherapy for cryptococcosis. / Hospenthal, Duane R.; Bennett, John E.

In: Clinical Infectious Diseases, Vol. 27, No. 2, 1998, p. 260-264.

Research output: Contribution to journalArticle

Hospenthal, DR & Bennett, JE 1998, 'Flucytosine monotherapy for cryptococcosis', Clinical Infectious Diseases, vol. 27, no. 2, pp. 260-264.
Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clinical Infectious Diseases. 1998;27(2):260-264.
Hospenthal, Duane R. ; Bennett, John E. / Flucytosine monotherapy for cryptococcosis. In: Clinical Infectious Diseases. 1998 ; Vol. 27, No. 2. pp. 260-264.
@article{d9cb332267a44e3ab9149ac95c7cd15b,
title = "Flucytosine monotherapy for cryptococcosis",
abstract = "Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. Reported documentation of this widely accepted belief is surprisingly scarce. Therefore, we reviewed our experience with 5-FC monotherapy for 27 patients treated between 1968 and 1973. Patients were selected on the basis of criteria associated with good prognosis. In this group, 5-FC monotherapy resulted in cure in eight cases and improvement in two. Overall, response was seen in 10 (43{\%}) of 23 evaluable patients. Therapy failed for 13 patients, including 5 who relapsed, 2 who had partial responses, and 6 without response. Resistance was noted to have developed in isolates from six (50{\%}) of 12 patients for whom therapy failed. Although the 57{\%} failure rate associated with 5-FC alone precludes its use as monotherapy, our study did show that this treatment was well tolerated and that failure was not invariably associated with development of resistance.",
author = "Hospenthal, {Duane R.} and Bennett, {John E.}",
year = "1998",
language = "English (US)",
volume = "27",
pages = "260--264",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Flucytosine monotherapy for cryptococcosis

AU - Hospenthal, Duane R.

AU - Bennett, John E.

PY - 1998

Y1 - 1998

N2 - Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. Reported documentation of this widely accepted belief is surprisingly scarce. Therefore, we reviewed our experience with 5-FC monotherapy for 27 patients treated between 1968 and 1973. Patients were selected on the basis of criteria associated with good prognosis. In this group, 5-FC monotherapy resulted in cure in eight cases and improvement in two. Overall, response was seen in 10 (43%) of 23 evaluable patients. Therapy failed for 13 patients, including 5 who relapsed, 2 who had partial responses, and 6 without response. Resistance was noted to have developed in isolates from six (50%) of 12 patients for whom therapy failed. Although the 57% failure rate associated with 5-FC alone precludes its use as monotherapy, our study did show that this treatment was well tolerated and that failure was not invariably associated with development of resistance.

AB - Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. Reported documentation of this widely accepted belief is surprisingly scarce. Therefore, we reviewed our experience with 5-FC monotherapy for 27 patients treated between 1968 and 1973. Patients were selected on the basis of criteria associated with good prognosis. In this group, 5-FC monotherapy resulted in cure in eight cases and improvement in two. Overall, response was seen in 10 (43%) of 23 evaluable patients. Therapy failed for 13 patients, including 5 who relapsed, 2 who had partial responses, and 6 without response. Resistance was noted to have developed in isolates from six (50%) of 12 patients for whom therapy failed. Although the 57% failure rate associated with 5-FC alone precludes its use as monotherapy, our study did show that this treatment was well tolerated and that failure was not invariably associated with development of resistance.

UR - http://www.scopus.com/inward/record.url?scp=0031928924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928924&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 260

EP - 264

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -